S&P BSE Rejig: Honasa Consumer added to BSE FMCG Index, Tata Tech to BSE IT Index
On the other hand, Gulshan Polymers has been dropped from S&P BSE Commodities, UPL from S&P BSE India Manufacturing Index
BSE has announced the latest rejig of its indices with additions and removal in around 17 indices. These changes will be in place from March 18. As per the release, no changes will be made in the S&P BSE Bharat 22 Index, S&P BSE REIT & InvIT Index (INR), S&P BSE Telecommunication and S&P BSE Private Banks Index
The recently listed Honasa Consumer has been added to the S&P BSE Fast Moving Consumer Goods Index along with Doms Industries, Flair Writing Industries, HMA Agro Industries, ML Proteins and Gulshan Polytols.
Stocks such as Jio Financial Services Ltd, Indian Renewable Energy Development Agency Ltd, SBFC Finance Ltd, India Shelter Finance Corporation Ltd, Utkarsh Small Finance Bank Ltd, Fedbank Financial Services Ltd, Nuvama Wealth Management Ltd.Muthoot Microfin Ltd
ESAF Small Finance Bank Ltd have been included in the S&P Financial Services.
The S&P BSE Information Technology Index will now include Tata Technologies, Netweb Technologies India, Protean eGov Technologies, and Zaggle Prepaid Ocean Services.
Concord Biotech, Jupiter Life Line Hospitals, Blue Jet Healthcare Limited, Yatharth Hospital & Trauma Care Services and Innova Captab have been added to the S&P BSE Healthcare Index.
On the other hand, Gulshan Polymers has been dropped from S&P BSE Commodities, UPL from S&P BSE India Manufacturing Index and KNR Constructions from S&P BSE India Infrastructure Index amongst others.
Aurobindo Pharma arm gets WHO GMP approval; shares flat
The Prequalification Unit Inspection Team (PQT-INS) of World Health organization (WHO) had conducted an inspection at the Unit IV from September 11 to September 15, 2023.
Aurobindo Pharma share price was trading flat on March 12 after the company's subsidiary received WHO GMP approval.
At 09:56 am Aurobindo Pharma was quoting at Rs 1,063.90, down Rs 0.45, or 0.04 percent, on the BSE.
The Prequalification Unit Inspection Team (PQT-INS) of the World Health organization (WHO) had inspected the Unit IV, a formulation manufacturing facility of a wholly owned subsidiary, APL Healthcare, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, between September 11 and September 15, 2023.
Based on the inspection findings and our response to the same, the PQT-INS has decided to recommend to the Prequalification Assessment Team that the above facility be named as a manufacturing site in the dossier for Dolutegravir, Lamivudine, Tenofovir Disoproxil Fumarate Tablets (50/300/300 mg), the company said.
On March 1, the company received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fingolimod Capsules, 0.5 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation. The product will be launched in March 2024.
In February, the company received seven observations from the United States Food and Drug Administration (USFDA) after inspecting the injectable facility of Eugia SEZ Pvt Ltd, a 100 percent step-down subsidiary of Aurobindo Pharma Ltd, at Polepally Village in Mahaboobnagar district of Telangana, from February 19 to 29.
Source: Money Control
Comments
Post a Comment